{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T01:38:21Z","timestamp":1777426701175,"version":"3.51.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Irish Department of Foreign Affairs (Global Health Research Board grant to the Haughton Institute)"},{"name":"Bill and Melinda Gates Foundation (ACT Consortium grant to LSHTM)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12879-016-1345-1","type":"journal-article","created":{"date-parts":[[2016,1,27]],"date-time":"2016-01-27T02:34:30Z","timestamp":1453862070000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["The interaction between artemether-lumefantrine and lopinavir\/ritonavir-based antiretroviral therapy in HIV-1 infected patients"],"prefix":"10.1186","volume":"16","author":[{"given":"T.","family":"Kredo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Mauff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Workman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. S.","family":"Van der Walt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Wiesner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. J.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Maartens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. I.","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,1,27]]},"reference":[{"key":"1345_CR1","unstructured":"World Health Organization. World Malaria Report 2014. Switzerland: World Health Organization. [Available from: http:\/\/www.who.int\/malaria\/publications\/world_malaria_report_2014\/wmr-2014-no-profiles.pdf ]."},{"issue":"4","key":"1345_CR2","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.pt.2008.01.006","volume":"24","author":"NJ White","year":"2008","unstructured":"White NJ, Stepniewska K, Barnes K, Price RN, Simpson J. Simplified antimalarial therapeutic monitoring: using the day-7 drug level? Trends Parasitol. 2008;24(4):159\u201363.","journal-title":"Trends Parasitol"},{"key":"1345_CR3","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/1475-2875-6-122","volume":"6","author":"KI Barnes","year":"2007","unstructured":"Barnes KI, Lindegardh N, Ogundahunsi O, Olliaro P, Plowe CV, Randrianarivelojosia M, et al. World Antimalarial Resistance Network (WARN) IV: clinical pharmacology. Malar J. 2007;6:122.","journal-title":"Malar J"},{"issue":"2","key":"1345_CR4","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/00003088-199937020-00002","volume":"37","author":"NJ White","year":"1999","unstructured":"White NJ, van Vugt M, Ezzet F. Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine. Clin Pharmacokinet. 1999;37(2):105\u201325.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"1345_CR5","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1128\/AAC.44.3.697-704.2000","volume":"44","author":"F Ezzet","year":"2000","unstructured":"Ezzet F, van Vugt M, Nosten F, Looareesuwan S, White NJ. Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob Agents Chemother. 2000;44(3):697\u2013704.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"1345_CR6","doi-asserted-by":"crossref","first-page":"e253","DOI":"10.1371\/journal.pmed.0050253","volume":"5","author":"R McGready","year":"2008","unstructured":"McGready R, Tan SO, Ashley EA, Pimanpanarak M, Viladpai-Nguen J, Phaiphun L, et al. A randomised controlled trial of artemether-lumefantrine versus artesunate for uncomplicated plasmodium falciparum treatment in pregnancy. PLoS Med. 2008;5(12):e253.","journal-title":"PLoS Med"},{"key":"1345_CR7","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1475-2875-5-59","volume":"5","author":"F Checchi","year":"2006","unstructured":"Checchi F, Piola P, Fogg C, Bajunirwe F, Biraro S, Grandesso F, et al. Supervised versus unsupervised antimalarial treatment with six-dose artemether-lumefantrine: pharmacokinetic and dosage-related findings from a clinical trial in Uganda. Malar J. 2006;5:59.","journal-title":"Malar J"},{"issue":"9","key":"1345_CR8","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.trstmh.2008.05.022","volume":"102","author":"MM Rahman","year":"2008","unstructured":"Rahman MM, Dondorp AM, Day NP, Lindegardh N, Imwong M, Faiz MA, et al. Adherence and efficacy of supervised versus non-supervised treatment with artemether\/lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Bangladesh: a randomised controlled trial. Trans R Soc Trop Med Hyg. 2008;102(9):861\u20137.","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"11","key":"1345_CR9","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1086\/503423","volume":"42","author":"RN Price","year":"2006","unstructured":"Price RN, Uhlemann AC, van Vugt M, Brockman A, Hutagalung R, Nair S, et al. Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria. Clin Infect Dis. 2006;42(11):1570\u20137.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"1345_CR10","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1111\/j.1365-3156.2006.01739.x","volume":"11","author":"MB Denis","year":"2006","unstructured":"Denis MB, Tsuyuoka R, Lim P, Lindegardh N, Yi P, Top SN, et al. Efficacy of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Cambodia. Trop Med Int Health. 2006;11(12):1800\u20137.","journal-title":"Trop Med Int Health"},{"issue":"1","key":"1345_CR11","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/s12916-015-0456-7","volume":"13","author":"WorldWide Antimalarial Resistance Network (WWARN) Lumefantrine PK\/PD Study Group","year":"2015","unstructured":"WorldWide Antimalarial Resistance Network (WWARN) Lumefantrine PK\/PD Study Group. Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient data. BMC Med. 2015;13(1):227.","journal-title":"BMC Med"},{"key":"1345_CR12","unstructured":"World Health Organization. Guidelines for the treatment of malaria. Switzerland: World Health Organization. 2015. 3rd edition: [Available from: http:\/\/www.who.int\/malaria\/publications\/atoz\/9789241549127\/en\/ ]"},{"issue":"9","key":"1345_CR13","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.2165\/00003495-200666090-00012","volume":"66","author":"V Oldfield","year":"2006","unstructured":"Oldfield V, Plosker GL. Lopinavir\/Ritonavir: a review of its use in the management of HIV infection. Drugs. 2006;66(9):1275\u201399.","journal-title":"Drugs"},{"issue":"10","key":"1345_CR14","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1097\/01.aids.0000174445.40379.e0","volume":"19","author":"S Khoo","year":"2005","unstructured":"Khoo S, Back D, Winstanley P. The potential for interactions between antimalarial and antiretroviral drugs. AIDS. 2005;19(10):995\u20131005.","journal-title":"AIDS"},{"issue":"7","key":"1345_CR15","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1473-3099(11)70031-7","volume":"11","author":"C Flateau","year":"2011","unstructured":"Flateau C, Le Loup G, Pialoux G. Consequences of HIV infection on malaria and therapeutic implications: a systematic review. Lancet Infect Dis. 2011;11(7):541\u201356.","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"1345_CR16","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1128\/AAC.05265-11","volume":"55","author":"T Kredo","year":"2011","unstructured":"Kredo T, Mauff K, Van der Walt JS, Wiesner L, Maartens G, Cohen K, et al. Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients. Antimicrob Agents Chemother. 2011;55(12):5616\u201323.","journal-title":"Antimicrob Agents Chemother"},{"key":"1345_CR17","volume-title":"National antiretroviral treatment guidelines","author":"South African National Department of Health","year":"2004","unstructured":"South African National Department of Health. National antiretroviral treatment guidelines. 1st ed. Pretoria Jacana: Department of Health SA; 2004.","edition":"1"},{"issue":"10","key":"1345_CR18","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1177\/009127002401382632","volume":"42","author":"G Lefevre","year":"2002","unstructured":"Lefevre G, Carpenter P, Souppart C, Schmidli H, Martin JM, Lane A, et al. Interaction trial between artemether-lumefantrine (Riamet) and quinine in healthy subjects. J Clin Pharmacol. 2002;42(10):1147\u201358.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"1345_CR19","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1046\/j.1365-2125.2002.01696.x","volume":"54","author":"G Lefevre","year":"2002","unstructured":"Lefevre G, Carpenter P, Souppart C, Schmidli H, McClean M, Stypinski D. Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects. Br J Clin Pharmacol. 2002;54(5):485\u201392.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"1345_CR20","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1540-8167.2006.00408.x","volume":"17","author":"I Goldenberg","year":"2006","unstructured":"Goldenberg I, Moss AJ, Zareba W. QT interval: how to measure it and what is \u201cnormal\u201d. J Cardiovasc Electrophysiol. 2006;17(3):333\u20136.","journal-title":"J Cardiovasc Electrophysiol"},{"key":"1345_CR21","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1186\/1475-2875-12-325","volume":"12","author":"EN Allen","year":"2013","unstructured":"Allen EN, Chandler CI, Mandimika N, Pace C, Mehta U, Barnes KI. Evaluating harm associated with anti-malarial drugs: a survey of methods used by clinical researchers to elicit, assess and record participant-reported adverse events and related data. Malar J. 2013;12:325.","journal-title":"Malar J"},{"issue":"1","key":"1345_CR22","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/1471-2288-13-140","volume":"13","author":"EN Allen","year":"2013","unstructured":"Allen EN, Mushi AK, Massawe IS, Vestergaard LS, Lemnge M, Staedke SG, et al. How experiences become data: the process of eliciting adverse event, medical history and concomitant medication reports in antimalarial and antiretroviral interaction trials. BMC Med Res Methodol. 2013;13(1):140.","journal-title":"BMC Med Res Methodol"},{"issue":"6","key":"1345_CR23","doi-asserted-by":"crossref","first-page":"964","DOI":"10.4269\/ajtmh.1999.61.964","volume":"61","author":"M Vugt van","year":"1999","unstructured":"van Vugt M, Ezzet F, Nosten F, Gathmann I, Wilairatana P, Looareesuwan S, et al. No evidence of cardiotoxicity during antimalarial treatment with artemether-lumefantrine. Am J Trop Med Hyg. 1999;61(6):964\u20137.","journal-title":"Am J Trop Med Hyg"},{"key":"1345_CR24","first-page":"393976","volume":"2011","author":"P Byakika-Kibwika","year":"2011","unstructured":"Byakika-Kibwika P, Lamorde M, Lwabi P, Nyakoojo WB, Okaba-Kayom V, Mayanja-Kizza H, et al. Cardiac conduction safety during Coadministration of Artemether-lumefantrine and Lopinavir\/Ritonavir in HIV-infected Ugandan adults. Chemother Res Pract. 2011;2011:393976.","journal-title":"Chemother Res Pract"},{"issue":"5","key":"1345_CR25","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1093\/jac\/dkr596","volume":"67","author":"P Byakika-Kibwika","year":"2012","unstructured":"Byakika-Kibwika P, Lamorde M, Okaba-Kayom V, Mayanja-Kizza H, Katabira E, Hanpithakpong W, et al. Lopinavir\/ritonavir significantly influences pharmacokinetic exposure of artemether\/lumefantrine in HIV-infected Ugandan adults. J Antimicrob Chemother. 2012;67(5):1217\u201323.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"1345_CR26","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0924-8579(99)00063-1","volume":"12","author":"MA Agtmael van","year":"1999","unstructured":"van Agtmael MA, Cheng-Qi S, Qing JX, Mull R, van Boxtel CJ. Multiple dose pharmacokinetics of artemether in Chinese patients with uncomplicated falciparum malaria. Int J Antimicrob Agents. 1999;12(2):151\u20138.","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"1345_CR27","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1053\/cp.1999.v66.a101946","volume":"66","author":"MA Agtmael van","year":"1999","unstructured":"van Agtmael MA, Gupta V, van der Graaf CAA, van Boxtel CJ. The effect of grapefruit juice on the time-dependent decline of artemether plasma levels in healthy subjects[ast]. Clin Pharmacol Ther. 1999;66(4):408\u201314.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"1345_CR28","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00228-002-0485-y","volume":"58","author":"US Svensson","year":"2002","unstructured":"Svensson US, Alin H, Karlsson MO, Bergqvist Y, Ashton M. Population pharmacokinetic and pharmacodynamic modelling of artemisinin and mefloquine enantiomers in patients with falciparum malaria. Eur J Clin Pharmacol. 2002;58(5):339\u201351.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"1345_CR29","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1097\/QAI.0b013e3181acb4ff","volume":"51","author":"P German","year":"2009","unstructured":"German P, Parikh S, Lawrence J, Dorsey G, Rosenthal PJ, Havlir D, et al. Lopinavir\/ritonavir affects pharmacokinetic exposure of artemether\/lumefantrine in HIV-uninfected healthy volunteers. J Acquir Immune Defic Syndr. 2009;51(4):424\u20139.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"1345_CR30","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/bcp.12529","volume":"79","author":"RM Hoglund","year":"2015","unstructured":"Hoglund RM, Byakika-Kibwika P, Lamorde M, Merry C, Ashton M, Hanpithakpong W, et al. Artemether-lumefantrine co-administration with antiretrovirals: population pharmacokinetics and dosing implications. Br J Clin Pharmacol. 2015;79(4):636\u201349.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"1345_CR31","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1314981","volume":"371","author":"EA Ashley","year":"2014","unstructured":"Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014;371(5):411\u201323.","journal-title":"N Engl J Med"},{"key":"1345_CR32","volume-title":"Emergency response to artemisinin resistance in the Greater Mekong subregion. Regional Framework for Action 2013\u20132015","author":"World Health Organization","year":"2013","unstructured":"World Health Organization. Emergency response to artemisinin resistance in the Greater Mekong subregion. Regional Framework for Action 2013\u20132015. 2013. Available from: http:\/\/www.who.int\/malaria\/publications\/atoz\/9789241505321\/en\/ ."},{"issue":"4","key":"1345_CR33","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1473-3099(15)70032-0","volume":"15","author":"KM Tun","year":"2015","unstructured":"Tun KM, Imwong M, Lwin KM, Win AA, Hlaing TM, Hlaing T, et al. Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker. Lancet Infect Dis. 2015;15(4):415\u201321.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"1345_CR34","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1128\/AAC.00679-09","volume":"54","author":"J Mwesigwa","year":"2010","unstructured":"Mwesigwa J, Parikh S, McGee B, German P, Drysdale T, Kalyango JN, et al. Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda. Antimicrob Agents Chemother. 2010;54(1):52\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"22","key":"1345_CR35","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMoa1200501","volume":"367","author":"J Achan","year":"2012","unstructured":"Achan J, Kakuru A, Ikilezi G, Ruel T, Clark TD, Nsanzabana C, et al. Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children. N Engl J Med. 2012;367(22):2110\u20138.","journal-title":"N Engl J Med"},{"issue":"3","key":"1345_CR36","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1093\/cid\/ciu286","volume":"59","author":"A Kakuru","year":"2014","unstructured":"Kakuru A, Achan J, Muhindo MK, Ikilezi G, Arinaitwe E, Mwangwa F, et al. Artemisinin-based combination therapies are efficacious and safe for treatment of uncomplicated malaria in HIV-infected Ugandan children. Clin Infect Dis. 2014;59(3):446\u201353.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"1345_CR37","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1365-3156.2006.01785.x","volume":"12","author":"EA Ashley","year":"2007","unstructured":"Ashley EA, Stepniewska K, Lindegardh N, McGready R, Annerberg A, Hutagalung R, et al. Pharmacokinetic study of artemether-lumefantrine given once daily for the treatment of uncomplicated multidrug-resistant falciparum malaria. Trop Med Int Health. 2007;12(2):201\u20138.","journal-title":"Trop Med Int Health"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-016-1345-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T01:14:15Z","timestamp":1567559655000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.biomedcentral.com\/1471-2334\/16\/30"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["1345"],"URL":"https:\/\/doi.org\/10.1186\/s12879-016-1345-1","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12]]},"article-number":"30"}}